https://repositorio.ufms.br/handle/123456789/4221 2026-04-15T02:26:11Z https://repositorio.ufms.br/handle/123456789/12680 Título: Núcleo de avaliação de tecnologias em saúde - NATS-Humap/UFMS Abstract: To facilitate the research, we conducted a search in the PubMed and Virtual Health Library (VHL) databases, using the controlled descriptors (MeSH/DeCS) "Teaching Rounds" and "Patient Safety," combined with the Boolean operators OR and AND. The free terms "Daily Huddle" and "Projeto Terapêutico Singular/Single Therapeutic Project" were also used, due to the specificity of these instruments, especially the PTS in the Brazilian context. Systematic reviews, literature reviews, and scoping reviews were selected, in addition to including materials found in additional readings from the last 20 years. There were no language restrictions for the search. Tipo: Resposta Rápida https://repositorio.ufms.br/handle/123456789/6238 Título: NOTA TÉCNICA DE RESPOSTA RÁPIDA (NTRR) - Nº 002/2023 AFLIBERCEPTE Abstract: Title/question: What is the budgetary impact of Aflibercept compared to Ranibizumab, for the treatment of patients with Diabetic Macular Edema involving the center of the fovea, within the framework of the University Hospital Maria Aparecida Pedrossian, Humap-UFMS/Ebserh. Target Population: Patients affected by Diabetic Macular Edema involving the center of the fovea. Technology: Aflibercept (Eylia®) Comparator: Ranibizumab (Lucentis®) Search for practiced prices: the cost of each bottle of Aflibercept in this NTRR was estimated at BRL 3,852.36, according to the average calculated and Ranibizumab was BRL 2,751.78. Budget Impact: As provided in the merger order, 30 vials of Aflibercept per month would be required. Therefore, the estimated annual cost would be R$ 1,386,849.60. Despite having a SUS code related to the procedure, there would be an annual deficit of R$ 1,161,028.80. Conclusion: The PCDT of Diabetic Retinopathy shows that both Aflibercept and Ranibizumab are safe and effective therapeutic options to treat it. Evidence points out that Ranibizumab has a smaller budgetary impact, but that both are not fully reimbursed by the SUS table. Recommendations: It is recommended that the applicant evaluate Ranibizumab as a therapeutic option for the treatment of diabetic retinopathy, and it is up to the administrative manager to analyze, in the light of the data presented here, whether the incorporation of either or both is financially viable. Tipo: Parecer Técnico https://repositorio.ufms.br/handle/123456789/5658 Título: Carboximaltose Férrica Abstract: Technology: Ferric Carboxymaltose (CMF) is a complex of colloidal iron hydroxide with stronger binding of elemental iron to carbohydrate polymer than some other preparations of iron IV. CMF can be administered in a single dose of up to 1,000 mg of elemental iron (20 ml of a solution of 50 mg of elemental iron/ml). European product labeling specifies a Maximum single dose of 20 mg/kg body weight. Product labeling in the United States specifies a maximum single dose of 15 mg/kg body weight. Indication: CMF labeled indications are for the treatment of iron deficiency anemia. iron in adults (ADF) and pediatric patients ≥1 year of age with intolerance to oral iron or unsatisfactory response to oral iron and for the treatment of ADF in adults with chronic kidney disease not dependent on dialysis. Otherwise, Off-Label use in adults applies for surgery abdominal pain (management of perioperative anemia), anemia associated with chemotherapy, anemia due to iron deficiency in inflammatory bowel disease; iron deficiency in heart failure with reduced ejection fraction and restless legs syndrome. Questions: (i) Is IV Iron Carboxymaltose effective and safe to reduce the need for transfusion of red blood cells in the treatment of iron deficiency anemia in patients in the pre and postoperative period of surgery cardiac? (ii) If the previous question is yes, what is the local budget impact of its incorporation within a 12-month horizon? Methods: Searches were carried out in electronic databases: Pubmed, VHL Regional Portal, Scopus and Web of Science, totaling 116 studies. After excluding duplicates, the screening was performed by two reviewers independently based on their titles and abstracts. the publications remainders were read in full, excluding those that did not meet the criteria for previously established eligibility. Results: In the end, five studies were included for analysis of this NTRR, three studies observational and two randomized clinical trials. Of the five studies, four pointed favorable results for the use of CMF to reduce the need for red blood cell transfusion in the treatment of iron deficiency anemia in patients with indication for cardiac surgery and in the postoperative period. The expected budget impact for one year is BRL 221,400.00, considering the annual consumption of 360 ampoules at a unit cost of R$ 615.00 per ampoule. Conclusion: According to the findings gathered in this NTRR, it is recommended for the specific use of this technical note the incorporation of iron CMF for the treatment of adult patients with anemia due to iron deficiency with indication for cardiac surgery. Tipo: Resposta Rápida https://repositorio.ufms.br/handle/123456789/5137 Título: Uso de agente paralisante da função neuromuscular aplicado no tratamento de comorbidades relacionadas à região de cabeça e pescoço de pacientes atendidos do Humap-UFMS/EBSERH, a partir do emprego da Toxina Botulínica Tipo A (TBA) Abstract: Demand submitted by the Head and Neck Unit UCA/DGC/GAS/Humap-UFMS to the Center for Health Technology Assessment (NATS) at the Maria Aparecida Pedrossian University Hospital HumapUFMS/Ebserh for the use of a neuromuscular function paralyzing agent applied in the treatment of comorbidities related to the head and neck region of patients treated at Humap-UFMS/EBSERH, from use of Botulinum Toxin Type A (TBA). Obtained in the laboratory, TBA is a biological agent, with a stable crystalline appearance, lyophilized in human albumin, preserved in a sterile vacuum flask, with dilution in saline solution. Of eight serological types of toxin produced by the anaerobic bacterium, Clostridium botulinum, the most potent is type A, which is of clinical use (SPOSITO, 2004). Tipo: Parecer Técnico 2022-09-30T00:00:00Z